Adopted Trials - Malignant melanoma
Acronym: SUAVE
Full Title
A Randomised Phase II Study of Sunitinib versus Dacarbazine in the Treatment of Patients with Metastatic Uveal Melanom
Treatment: Small molecule (indirect & direct acting) (cytotoxic/targeted)
Phase: 2
Current status: In set-up
Chief Investigator: Dr Ernie Marshall
Type of trial: Early Phase
Website:
Acronym: High Dose Interferon
Full Title
Phase II pilot study of intravenous high dose interferon with or without maintenance treatment in melanoma at high risk of recurrence
Treatment: Other complex biological therapies
Phase: 2
Current status: Closed to recruitment - in follow-up
Chief Investigator: Dr Mark Middleton
Type of trial: Early Phase
Website:
Acronym: ITEM
Full Title
A single arm phase II study of Imatinib in good performance status patients with C-Kit positive metastatic Uveal Melanoma
Treatment: Small molecule (indirect & direct acting) (cytotoxic/targeted)
Phase: 2
Current status: Closed to recruitment - in follow-up
Chief Investigator: Dr Ernie Marshall
Type of trial: Early Phase
Acronym: PROGENOM
Full Title
Proteomic and Genomic Analysis of Ocular Melanoma
Treatment: Biomarkers
Phase: N/A
Current status: Open to recruitment
Chief Investigator: Dr Sarah Coupland
Type of trial: Biomarkers
Website:
Acronym: M10-440
Full Title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination with Temozolomide Versus Temozolomide Alone in Subjects with Metastatic Melanoma
Treatment: Chemotherapy
Phase: 2
Current status: Open to recruitment
Chief Investigator: Dr Mark Middleton
Type of trial: Early Phase
Website:
